Hpgc Renmintongtai Pharmaceutical Corporation Warns of Risks After Four Consecutive Limit-Up Sessions

Deep News2025-11-13

On the evening of November 13, Hpgc Renmintongtai Pharmaceutical Corporation (600829) issued an announcement stating that its stock price had surged by a cumulative deviation of 20% over two consecutive trading days on November 12 and 13, triggering an abnormal trading volatility alert under Shanghai Stock Exchange regulations.

The company conducted a self-review and consulted its controlling shareholder, Harbin Pharmaceutical Group Co., Ltd., and its indirect controlling shareholder, Harbin Pharmaceutical Group Holding Co., Ltd., confirming no undisclosed material events or information.

Hpgc Renmintongtai emphasized that its stock price surge significantly outpaced both the industry index and the Shanghai Composite Index, posing a risk of rapid decline. From November 10 to November 13, the stock hit the daily limit-up for four consecutive sessions, accumulating a 46.43% gain. In contrast, the Shanghai Composite Index rose only 0.8%, while the pharmaceutical commerce sector (Shenwan) gained 4.53% during the same period.

The company clarified that its core business operations remain unchanged. The rapid short-term price increase reflects overheated market sentiment and speculative risks, which may lead to a sudden downturn.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133669739?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133669739","market":"fut","top_or_hot":-1,"title":"Hpgc Renmintongtai Pharmaceutical Corporation Warns of Risks After Four Consecutive Limit-Up Sessions","media":"Deep News","content":"<p>On the evening of November 13, Hpgc Renmintongtai Pharmaceutical Corporation (600829) issued an announcement stating that its stock price had surged by a cumulative deviation of 20% over two consecutive trading days on November 12 and 13, triggering an abnormal trading volatility alert under Shanghai Stock Exchange regulations.</p>\n<p>The company conducted a self-review and consulted its controlling shareholder, Harbin Pharmaceutical Group Co., Ltd., and its indirect controlling shareholder, Harbin Pharmaceutical Group Holding Co., Ltd., confirming no undisclosed material events or information.</p>\n<p>Hpgc Renmintongtai emphasized that its stock price surge significantly outpaced both the industry index and the Shanghai Composite Index, posing a risk of rapid decline. From November 10 to November 13, the stock hit the daily limit-up for four consecutive sessions, accumulating a 46.43% gain. In contrast, the Shanghai Composite Index rose only 0.8%, while the pharmaceutical commerce sector (Shenwan) gained 4.53% during the same period.</p>\n<p>The company clarified that its core business operations remain unchanged. The rapid short-term price increase reflects overheated market sentiment and speculative risks, which may lead to a sudden downturn.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hpgc Renmintongtai Pharmaceutical Corporation Warns of Risks After Four Consecutive Limit-Up Sessions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHpgc Renmintongtai Pharmaceutical Corporation Warns of Risks After Four Consecutive Limit-Up Sessions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-11-13 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On the evening of November 13, Hpgc Renmintongtai Pharmaceutical Corporation (600829) issued an announcement stating that its stock price had surged by a cumulative deviation of 20% over two consecutive trading days on November 12 and 13, triggering an abnormal trading volatility alert under Shanghai Stock Exchange regulations.</p>\n<p>The company conducted a self-review and consulted its controlling shareholder, Harbin Pharmaceutical Group Co., Ltd., and its indirect controlling shareholder, Harbin Pharmaceutical Group Holding Co., Ltd., confirming no undisclosed material events or information.</p>\n<p>Hpgc Renmintongtai emphasized that its stock price surge significantly outpaced both the industry index and the Shanghai Composite Index, posing a risk of rapid decline. From November 10 to November 13, the stock hit the daily limit-up for four consecutive sessions, accumulating a 46.43% gain. In contrast, the Shanghai Composite Index rose only 0.8%, while the pharmaceutical commerce sector (Shenwan) gained 4.53% during the same period.</p>\n<p>The company clarified that its core business operations remain unchanged. The rapid short-term price increase reflects overheated market sentiment and speculative risks, which may lead to a sudden downturn.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0250","symbol_name":"批发","start_time":0,"source_url":"","article_id":"1133669739","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133669739","pubTimestamp":1763044258,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"On the evening of November 13, Hpgc Renmintongtai Pharmaceutical Corporation (600829) issued an announcement stating that its stock price had surged by a cumulative deviation of 20% over two...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600829":"人民同泰","BK0250":"批发"},"translate_title":"连续四个涨停板后，Hpgc人民同泰药业公司警告风险","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600829":1},"content_text":"On the evening of November 13, Hpgc Renmintongtai Pharmaceutical Corporation (600829) issued an announcement stating that its stock price had surged by a cumulative deviation of 20% over two consecutive trading days on November 12 and 13, triggering an abnormal trading volatility alert under Shanghai Stock Exchange regulations.\nThe company conducted a self-review and consulted its controlling shareholder, Harbin Pharmaceutical Group Co., Ltd., and its indirect controlling shareholder, Harbin Pharmaceutical Group Holding Co., Ltd., confirming no undisclosed material events or information.\nHpgc Renmintongtai emphasized that its stock price surge significantly outpaced both the industry index and the Shanghai Composite Index, posing a risk of rapid decline. From November 10 to November 13, the stock hit the daily limit-up for four consecutive sessions, accumulating a 46.43% gain. In contrast, the Shanghai Composite Index rose only 0.8%, while the pharmaceutical commerce sector (Shenwan) gained 4.53% during the same period.\nThe company clarified that its core business operations remain unchanged. The rapid short-term price increase reflects overheated market sentiment and speculative risks, which may lead to a sudden downturn.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133669739","isCrawlerRequest":true}